Benin vs Viet Nam: Average cost of multi drug-resistant tuberculosis treatment
Benin
426 constant 2022 US$
in 2024
Viet Nam
458 constant 2022 US$
in 2024
Benin rank
86th
Viet Nam rank
83rd
Average cost of multi drug-resistant tuberculosis treatment over time
- Benin
- Viet Nam
How they compare
Viet Nam currently reports 458 constant 2022 US$ against 426 constant 2022 US$ in Benin, a difference of 32 constant 2022 US$.
That makes Viet Nam's figure about 1.1 times Benin's.
The two have swapped places 4 times across 8 shared years of data; in 2017 it was Viet Nam ahead.
Benin ranks 86th and Viet Nam ranks 83rd of 92 countries.
Benin has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Benin | Viet Nam | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,013 constant 2022 US$ | 713 constant 2022 US$ | 300 constant 2022 US$ | Benin |
| 2020s | 865.8 constant 2022 US$ | 570.2 constant 2022 US$ | 295.6 constant 2022 US$ | Benin |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Benin or Viet Nam?
- Viet Nam, at 458 constant 2022 US$ against 426 constant 2022 US$ in Benin as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Benin and Viet Nam?
- 32 constant 2022 US$, with Viet Nam ahead.
- How many years of comparable data are there for Benin and Viet Nam?
- 8 years are reported by both, from 2017 to 2024.
- How do Benin and Viet Nam rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Benin ranks 86th and Viet Nam ranks 83rd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.